We aspire to surmount a universal problem for current and future targeted cancer therapies.

TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the response rates and durability of established treatments.

Read more


Our Approach

We have discovered a key mechanism that governs transcriptional resistance pathways.

Through a unique and novel approach to target identification and medicinal chemistry, we developed compounds capable of specifically blocking a critical mechanism upstream of transcriptional resistance programs without interfering with cancer-unrelated pathways.

Our lead candidate TT125-802 provides a novel opportunity to block therapeutic escape mechanisms in cancer.

TT125-802 is an orally available, selective small molecule inhibitor that blocks the transcription of genes involved in cancer cell resistance to targeted treatment.

Combining TT125-802 with targeted therapeutic agents for durable patient benefit

After a rapid dose escalation as monotherapy, we plan to advance TT125-802 with an innovative clinical development path that focuses on prevention of resistance by combining it with a range of targeted therapies.

We apply our expertise in non-genetic drug resistance to transform the cancer treatment landscape

With our team of experts in medicinal chemistry, bioinformatics and therapeutic development, we aim to deliver a novel therapeutic solution for cancer resistance for a broad range of targeted therapies.

Read more


Connect with us

Would you like to learn more about TOLREMO? Contact us at info@tolremo.com